🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06428734
Recruiting Observational

Clinical Outcome in Patients With INPH

NCT06428734 · tracked via the Priya Life Science China tracker
Sponsor
Xuanwu Hospital, Beijing
Phase
Observational
Started
2024-05-15
Last updated
2024-05-24

Condition(s) studied

HydrocephalusIdiopathic Normal Pressure HydrocephalusCSFGlympathic SystemOmic

Investigational drug(s) / intervention(s)

hydrocephalus groupnormal group

hydrocephalus group: Diagnostic Test: high throughput sequencing and electromyography Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS

normal group: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics and imaging, such as DTIALPS

Study summary

The aim of this study is to determine the clinical spectrum and natural progression of idiopathic normal pressure hydrocephalus (iNPH ) and related disorders in a prospective single center study, identify digital, imaging and molecular biomarkers that can assist in diagnosis and therapy development and study the etiology and molecular mechanisms of these diseases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * patients who was diagnosed as idiopathic normal pressure hydrocephalus Exclusion Criteria: * patient received surgical treatment or interventional treatment before patient is pregnant patient unable to complete follow-up patient with other types of hydrocephalus other nervous system diseases

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fengzeng Jian Beijing Beijing Municipality Recruiting

More Xuanwu Hospital, Beijing trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06428734 on ClinicalTrials.gov ↗ ← All trials in China